Variable Interest Entity

9 Months Ended

Jun. 30, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company has substantial governance rights over Profarma Distribuidora de Produtos Farmacêuticos S.A. (“Profarma”) that allow it to direct the activities that significantly impact Profarma’s economic performance. As such, the Company consolidates the operating results of Profarma in its consolidated financial statements. The Company is not obligated to provide future financial support to Profarma.

The following assets and liabilities of Profarma are included in the Company’s Consolidated Balance Sheets:


(in thousands)	June 30, 2026		September 30, 2025
Cash and cash equivalents	$	54,626	$	70,796
Accounts receivable, net	504,560		260,759
Inventories	397,753		303,480
Prepaid expenses and other	64,181		55,981
Property and equipment, net	81,457		65,410
Other intangible assets	50,669		53,861
Other long-term assets	111,860		99,519
Total assets	$	1,265,106	$	909,806

Accounts payable	$	514,894	$	349,876
Accrued expenses and other	127,506		71,383
Short-term debt	115,354		116,361
Long-term debt	116,539		65,390
Deferred income taxes	6,554		11,986
Other long-term liabilities	165,267		75,132
Total liabilities	$	1,046,114	$	690,128

Profarma’s assets can only be used to settle its obligations, and its creditors do not have recourse to the general credit of the Company.